Biophore receives DCGI nod to manufacture and export favipiravirJuly 17, 2020 0 By FM
Biophore India Pharmaceuticals has announced that the company received Drugs Controller General of India nod to manufacture and export anti-viral drug favipiravir for use in the treatment of mild to moderate COVID-19 cases.
Favipiravir is an oral antiviral drug with a unique activity against RNA viruses. Upon intake, the drug is converted to the ribofuranosyl triphosphate derivative by host enzymes which selectively inhibits the influenza viral RNA-dependent RNA polymerase enzyme necessary for their replication.
In India, Glenmark had previously received the DCGI approval for the use of the drug for treating mild to moderate COVID-19 cases upon completing the phase three clinical trial of favipiravir (Fabiflu).